# A Clinical Trial to Evaluate Clifutinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia(AML)

> **NCT04827069** · PHASE1 · COMPLETED · sponsor: **Sunshine Lake Pharma Co., Ltd.** · enrollment: 75 (actual)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** Clifutinib Besylate

## Key facts

- **NCT ID:** NCT04827069
- **Lead sponsor:** Sunshine Lake Pharma Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-05-18
- **Primary completion:** 2023-08-21
- **Final completion:** 2023-08-30
- **Target enrollment:** 75 (ACTUAL)
- **Last updated:** 2024-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04827069

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04827069, "A Clinical Trial to Evaluate Clifutinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia(AML)". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT04827069. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*